NEW YORK — According to published reports a vaccine developed by the University of Oxford in England is showing “promising” results, but scientists involved say it’s too soon to know if it will protect a wider population. Additional trials are now underway to understand if the injection, which helps the body to make antibodies and T-cells that can fight against coronavirus, will have similar results.

According to results published in The Lancet, the early-stage trial showed the vaccine called ChAdOx1 nCoV-19 is “safe, causes few side effects, and induces strong immune responses.” The vaccine is made from a virus that causes the common cold in chimpanzees, then its reengineered so as to not cause harm in humans and to give it more of a coronavirus structure. This means the vaccine resembles the coronavirus and will allow the bodies’  immune system to learn how to fight it. There are dozens of trials happening around the globe — finding one that works is of critical importance.

The study trialed 1,077 healthy adults between April 23 and May 21 and found participants making antibodies and white blood cells that can fight COVID-19. To date, the vaccine hasn’t shown any dangerous side effects, but 70% of people reported a fever or headache.